– USA, CA – Masimo (NASDAQ: MASI), a global innovator of noninvasive patient monitoring technologies, announced today that Adam Mikkelson, Partner at Camber Capital Management, LLC, has been elected to Masimo’s Board of Directors.
Mr. Mikkelson has been with Camber Capital Management, a healthcare-focused investment fund, since 2007. He has almost 15 years of experience in the healthcare investment arena, focused on identifying and actively monitoring opportunities in both the therapeutic and medical device sectors. He received his B.Sc. in Business Administration from Boston University.
“Adam’s investment experience and deep knowledge of the medical device industry made him an ideal candidate for Masimo’s Board of Directors,” said Joe Kiani, Founder, Chairman, and CEO of Masimo. “His insight into our complex health care system and his standing in the investment community will be invaluable.”
“I’m excited to be joining Masimo’s Board,” said Mr. Mikkelson. “As a healthcare investor, I’ve enjoyed watching Masimo grow over the years via the continued adoption of its innovative monitoring technologies. I hope that I can make positive contributions to an already strong Board to drive long-term value for Masimo and its shareholders.”
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index (ORi™), in addition to SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect™ (MOC-9™) interface. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor and the MightySat™ fingertip pulse oximeter.
For more information, visit www.masimo.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
